TY - JOUR T1 - Novel delivery of cellular therapy to reduce ischaemia reperfusion injury in kidney transplantation JF - medRxiv DO - 10.1101/19005546 SP - 19005546 AU - Emily R Thompson AU - Lucy Bates AU - Ibrahim K Ibrahim AU - Avinash Sewpaul AU - Ben Stenberg AU - Andrew McNeill AU - Rodrigo Figueiredo AU - Tom Girdlestone AU - Georgina C Wilkins AU - Ellen A Irwin AU - Samuel J Tingle AU - William E Scott III AU - Henrique Lamos AU - Andrew L. Mellor AU - Valerie D. Roobrouck AU - Anthony E. Ting AU - Sarah A Hosgood AU - Michael L Nicholson AU - Andrew J Fisher AU - Simi Ali AU - Neil S Sheerin AU - Colin H Wilson Y1 - 2019/01/01 UR - http://medrxiv.org/content/early/2019/09/08/19005546.abstract N2 - Ex-vivo normothermic machine perfusion (NMP) of donor kidneys prior to transplantation provides a platform for direct delivery of cellular therapeutics to optimise organ quality prior to transplantation. Multipotent Adult Progenitor Cells (MAPC®) possess potent immunomodulatory properties which could prove beneficial in minimising subsequent ischaemia reperfusion injury. We investigated the potential reconditioning capability of MAPC cells in kidney NMP.Methods Pairs (5) of human kidneys from the same donor were simultaneously perfused for 7 hours. The right or left kidney was randomly allocated to receive MAPC treatment. Serial samples of perfusate, urine and tissue biopsies were taken for comparison with the control paired kidney.Results MAPC-treated kidneys demonstrated improved urine output (p<0.01), decreased expression of the kidney injury biomarker NGAL (p<0.01), improved microvascular perfusion on contrast enhanced ultrasound (cortex p<0.05, medulla p<0.01), downregulation of IL-1β (p<0.05) and upregulation of IL-10 (p<0.05) and Indolamine-2, 3-dioxygenase (p<0.05). A mouse model of intraperitoneal chemotaxis demonstrated decreased neutrophil recruitment when stimulated with perfusate from MAPC-treated kidneys (p<0.01). Immunofluorescence revealed pre-labelled MAPC cells home to the perivascular space in the kidneys during NMP. MAPC therapy was not associated with detrimental physiological or embolic events.Conclusion We report the first successful delivery of cellular therapy to a kidney during NMP. Kidneys treated with MAPC cells demonstrate improvement in clinically relevant functional parameters and injury biomarkers. This novel method of cell therapy delivery provides an exciting opportunity to recondition organs prior to clinical transplantation.One Sentence Summary Ex-vivo reconditioning of human kidneys using Multipotent Adult Progenitor Cell therapy delivered during normothermic machine perfusion.Competing Interest StatementCompeting interests: VDR and AT are employees of ReGenesys and Athersys, Inc, respectively and are both shareholders of Athersys stock. The other authors declare that they have no competing interests.Funding StatementThis study was supported by Kidney Research UK, the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre and the NIHR Blood and Transplant Research Unit in Organ Donation and Transplantation at the University of Cambridge, in collaboration with Newcastle University and in partnership with National Health Service Blood and Transplant (NHSBT). The views expressed are those of the authors and not necessarily those of the National Health Services.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.Not ApplicableAll data related to this study are present in the paper or the Supplementary Materials. All reagents and perfusion consumables were commercially available. MAPC cells were obtained through the material transfer agreement between Newcastle University and Athersys Inc ER -